Exelixis Inc. (EXEL)
35.76
0.45 (1.27%)
At close: Apr 14, 2025, 3:54 PM
1.27% (1D)
| Bid | 35.69 |
| Market Cap | 10.01B |
| Revenue (ttm) | 2.17B |
| Net Income (ttm) | 521.27M |
| EPS (ttm) | 1.76 |
| PE Ratio (ttm) | 20.32 |
| Forward PE | 15.12 |
| Analyst | Buy |
| Ask | 35.84 |
| Volume | 1,512,114 |
| Avg. Volume (20D) | 2,752,918 |
| Open | 35.85 |
| Previous Close | 35.31 |
| Day's Range | 35.27 - 35.97 |
| 52-Week Range | 20.14 - 40.02 |
| Beta | 0.57 |
About EXEL
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CA...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 17, 2000
Employees 1,147
Stock Exchange NASDAQ
Ticker Symbol EXEL
Website https://www.exelixis.com
Analyst Forecast
According to 18 analyst ratings, the average rating for EXEL stock is "Buy." The 12-month stock price forecast is $39, which is an increase of 9.06% from the latest price.
Stock ForecastsNext Earnings Release
Exelixis Inc. is scheduled to release its earnings on Apr 29, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-0.03%
Exelixis shares are trading higher. Piper Sandler ...
Unlock content with
Pro Subscription
2 months ago
-5.13%
Exelixis shares are trading lower after Oppenheimer downgraded the stock from Outperform to Perform and cut its price target from $41 to $33.
